Moderated by Delegate Matthew Rohrbach (R - Cabell, 17)
Barry Glassman (R), County Executive, Hartford County, Maryland. He has served in both the Maryland House and Senate, where he was on the Senate Finance Committee. Executive Glassman was a key champion for Maryland’s Prescription Drug Affordability Board. The Board has the authority to make high-cost drugs more affordable for state and local governments. It also is charged with reviewing the rising cost of prescription drugs and submitting a plan to the Maryland General Assembly on how to make high-cost drugs more affordable for all Marylanders.
Jane Horvath, founder of the Center for Drug Pricing at the National Academy for State Health Policy (NASHP). Ms. Horvath has held research positions with Georgetown University Health Policy Institute, Johns Hopkins University, and MACPAC. Ms. Horvath spent ten years at Merck working on coverage and reimbursement policies in federal programs. She has worked for the Medicaid Directors, the US Senate Finance Committee, and was a Deputy Assistant Secretary for Legislation (Health) at the US Department of Health and Human Services.
Sarah K. Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER). ICER publishes an annual list of Rx drug “Unsupported Price Increases.”
ICER’s 2020 report highlights the seven drugs that experienced the most significant price increases in the U.S. in 2019, and had the most significant budget impact on the U.S. health system, resulting in an additional $1.2 billion in spending.
** Please register in advance for this meeting: